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Abstract. Background: Microsatellite instability (MSI) is a
biological characteristic of most tumours, being involved in 85%
of hereditary non-polyposis colorectal cancer (HNPCC). It also
occurs in 10-15% of sporadic colorectal cancers (CRC). HNPCC
appears to be caused by germline mutations in mismatch repair
(MMR) genes, which are responsible for repairing single base-pair
mismatches. MSI is also associated with a better response of CRC
to adjuvant chemotherapy with fluoropyrimidines. We investigated
any relationship between the MSI status and the TSmRNA
expression, the polymorphisms of 5-Fluorouracil (5-FU cellular
target, the enzyme thymidylate synthase (TS) and TS expression
evaluated by means of immunohistochemistry. Materials and
Methods: A series of 80 colorectal cancers was evaluated for MSI
and polymorphisms in the 3'UTR and the 5'UTR of the TS gene
by a PCR assay. TSmRNA was quantified by real-time PCR and
the TS expression by immunohistochemical assay. Results: There
was no significant association between the polymorphisms in the
TS gene and the MSI or between the TSmRNA expression and
the MSI status. CRC with a 3R/3R or 2R/3R genotype showed a
significantly higher TSmRNA expression than those with the
2R/2R genotype (p=0.001 and p=0.028, respectively). Another
significant association was found between the TSmRNA
expression and the TS immunohistochemical determination
(p=<0.05). No association was found between the polymorphism
of the 3'UTR and the TSmRNA expression. Conclusion: Our data
show that there is no association between MSI status and the
polymorphisms in the 3' and 5' UTRs and the TS expression.
Tumour samples displaying the 3R/3R or 2R/3R genotype of TS
have higher TSmRNA levels than the 2R/2R genotype.
Polymorphic variant of the 3'UTR does not influence the
TSmRNA level. We found a relationship between the TSmRNA
expression, evaluated by real-time PCR, and with the TS level
determined by immunohistochemical assay. Thus, genotyping of
the 5'UTR and quantification of the TSmRNA expression in
human CRC could be considered as predictors for response to
5FU-based chemotherapy. The evaluation of the TS expression by
means of immunohistochemistry assay remains a safe and reliable
assay in CRC. 
Major advances in the treatment of cancer have resulted
from the recent revolution in medical interventions.
Significant heterogeneity in the efficacy and toxicity of
chemotherapeutic agents is consistently observed across the
human population (1). 
Administration of the same dose of a given anticancer
drug to a population of patients results in a range of
toxicity, from unaffected to lethal events. While many
clinical variables have been associated with drug response
(age, gender, diet, organ function, tumour biology), genetic
differences in drug disposition and drug targets can have a
great impact on treatment outcome (1-3). 
The cellular targets for the majority of chemotherapy
agents contain genetic polymorphisms (4), but prospective
identification of patients likely to benefit from (or be
harmed by) chemotherapy is not currently possible for most
treatments. 
This is particularly important in the current health care
environment, where cost containment and evidence-based
initiatives are having a significant influence on patient care. 
Much research is being concentrated on isolating and
studying new genetic markers able to identify patients
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bearing tumours at high risk of progression or drug
resistance, one of them (MSI) with a possible role in the
therapeutic strategy of colorectal cancers (CRC). 
Microsatellites are small DNA sequences repeated in
tandem that show length polymorphisms and are found
throughout the human genome. Because they are repetitive,
microsatellites are prone to strand slippage and replication
errors (5). 
MSI occurs when there is disruption of the DNA mismatch-
repair system. Failure to repair mismatches can generate
mutations characterised by small insertions or deletions. Such
mutations alter microsatellite length and are visualised as
bandshifts on gel electrophoresis (6). MSI was first seen in
HNPCC (7) and is now known to occur in more than 90% of
colorectal cancers in individuals with this inherited
predisposition (5). About 15% of sporadic colorectal cancers
(those occurring without a familial predisposition) are MSI
(8). The MSI status of colorectal cancer has been assessed for
its prognostic value. Some studies found no survival difference
between tumours positive and negative for MSI (9), but they
were based on small samples and predated the routine use of
adjuvant chemotherapy. More recent studies report a
substantial survival advantage in MSI cancers compared with
microsatellite stability (MSS) cancers (8, 10), when they are
treated with 5-FU-based chemotherapy. The main antitumour
activity and cytotoxicity of this compound has been ascribed
to a potent inhibition of thymidylate synthase (TS). 
TS catalyses the conversion of dUMP to dTMP, the
source of thymidine nucleotides for DNA synthesis. 5-FU is
metabolised into the analogue FdUMP that inhibits, in a
competitive manner, the conversion of dUMP to dTMP,
which leads to the inhibition of DNA synthesis (11).TS levels
vary considerably among tumours and the response to 5-FU
is influenced by the intratumoural activity of the enzyme,
with high levels generally being associated with a poor
response (12, 13). TS expression has been shown to be
influenced both in vitro and in vivo by a polymorphic tandem
repeat sequence in the 5’-untranslated region (5’UTR).
Increasing the number of repeats leads to an increase in TS
expression (14, 15). Whether the polymorphism affects TS
expression on a transcriptional or translational level is
discussed controversially. Whereas Kawakami et al. (16)
concluded from their results that the three-repeat-sequence
confers a greater translational efficiency, Pullarkat et al. (17)
found a higher TS mRNA expression together with an
increasing number of tandem repeats. A recently detected 6-
bp deletion polymorphism in the 3’-untranslated region of
the TS gene might also influence transcriptional and/or
translational efficiency or mRNA stability (18).
Recently, studies were conducted to investigate whether
genotyping for the TS polymorphism might identify patients
with advanced CRC responding well to 5-FU-based
chemotherapy. The data suggested that patients homozygous
for the double tandem repeat compared to those with a
triple repeat had a survival benefit from 5-FU therapy or
therapy with the precursor molecule capecitabine (19-21).
The aim of this study was to investigate whether there was
a correlation between the MSI phenotype and the TS mRNA
levels and with the presence of the 5' and 3' UTR
polymorphisms in CRC. We analyzed the TS mRNA
expression by means of real-time PCR and the TS genotype
concerning the 3’UTR and 5’UTR which has been implicated
in influencing TS expression levels. As we performed the TS
mRNA levels in paraffin-embedded tumour samples using a
LightCycler–TS mRNA quantification Kit (Roche), we also
compared the TS mRNA levels obtained in this way with the
protein TS levels obtained by immunohistochemical method
using the monoclonal antibody 106, to show any difference
between the two assays. 
Materials and Methods
Cases. Formalin-fixed, paraffin-embedded samples retrieved from
archival material of 80 (previously untreated) patients affected by
primary colorectal cancer, were reviewed. Fifty patients were males
and 30 females. The age ranged from 40 to 90 years, with a mean
age of 65 years.
DNA extraction and MSI analysis. TS-positive cells were, through
microdissection, isolated from paraffin-embedded, formalin-fixed
specimens and DNA was extracted using the Dneasy tissue kit
purchased from Qiagen. The technique of microdissection allowed
molecular analysis of microsatellites instability only on tumour cells
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Figure 1. Schematic view of the TS gene polymorphic regions. A structure
of the TS 5’ UTR with the 3-or-2 repeat sequence. Horizontal arrows,
location of PCR primers. B structure of the TS 3’ flanking region with and
without the 6 bp insertion sequence. Capital letters, insertion sequence;
horizontal arrows, location of PCR primers; vertical arrow, restriction site
for Dral.
positive for TS and avoided contamination of normal tissue. The
following loci were examined: Bat-25, Bat-26, Bat-40, APC, D2S
123 and Mfd 15, according to international guidelines (22). DNA
was amplified through PCR techniques and PCR products were
carried out on polyacrilamide gel.
Polymerase chain reaction of the 5' UTR polymorphism. Polymerase
chain reaction analysis was performed amplifying 200 ng template
DNA in 20 Ìl of reaction mix including 10% of DMSO 1x reaction
buffer, MgCl2 at a final concentration of 3mM, 0.4 mM of each
primer, 0.2 mM dNTP and 1 U Taq polymerase (platinum Taq,
Invitrogen, Groningen, Netherlands).
Primers: Forward: 5'-AAA AGG CGC GCG GAA GGG GTC
CT-3'; reverse 5'- TCC GAG CCG GCC ACA GGC AT-3' were
used. After 35 cycles of amplification (94ÆC 40 sec, 62ÆC 40 sec,
72ÆC 40 sec), amplification products were electrophoresed in 3%
agarose gel. Products of 220 bp (2R/2R), and 248 bp (3R/3R), or
both of these products (2R/3R), depending on the TS genotype,
were obtained. 
Polymerase chain reaction of the 3' UTR polymorphism. The 3' UTR
analysis was carried out by polymerase chain restriction
amplification/RFLP analysis. Briefly, the fragment containing the
polymorphism was amplified by PCR as previously described by
Urlich et al. (23). As the presence of a 6bp insertion creates a Dral
restriction site, the amplified fragments were digested with this
enzyme and separated on 5% agarose gel.
LyghtCycler PCR for the quantification of TS expression. Total RNA
was extracted from five 5-mm paraffin sections. The tumour area
was scraped manually from the slide. Extraction was done using the
High Pure RNA Paraffin Kit (Roche, Mannheim, Germany)
according to the manufacturer’s instructions. cDNA synthesis and
subsequent PCR steps were performed using the LightCycler–TS
mRNA quantification Kit (Roche). Briefly, cDNA was reverse
transcribed from total RNA using AMV reverse transcriptase and
specific primers for the TS gene as well as for the reference gene
glucose-6-phosphate dehydrogenase (G6PDH). Afterwards,
fragments of the TS cDNA and the G6PDH cDNA were amplified
by PCR. The reaction mix with the solutions from the kit was
prepared and the appropriate amount of template DNA, as well as
the calibrator DNA provided with the kit, or PCR grade water as
negative control, were added. The amplicons were detected in
separate capillaries by using two specific pairs of fluorescence-
labelled hybridization probes. The fluorescence signals were
measured after each primer annealing step. 
Calculation of the relative amount of TS mRNA compared to
the reference gene was done using the LightCycler Relative
Quantification Software (Roche). The final results were expressed
as the ratio of TS/reference mRNA copies (T:R) in the samples
relative to the T:R ratio in the calibrator DNA. The T:R ratio in
the calibrator DNA has a value of one. 
Calascibetta et al: Polymorphism, Microsatellite Instability and Thymidylate Synthase Level in Colorectal Cancer
3877
Table I. Polymorphism in the 5’UTR of the TS gene in microsatellite
stable (MSS) and unstable (MSI) colorectal cancer.
2R/2R 2R/3R 3R/3R
MSI 15 (31.3%) 13 (28.1%) 20 (40.6%)
MSS 3 (9.5%) 15 (47.6%) 14 (42.9%)
Total 18 28 34
Table III. Immunohistochemical evaluation of the TS levels compared
with those obtained by RT PCR assay (p<0.05).
% of cells Patients n. Median TS/RT Min Max
positivity Ratio
Gr.1: 0 – 1+ 11 0.78 0.11 11.74
Gr.2: 2+ 15 2.82 0.41 7.64
Gr.3: 3+ – 4+ 17 4.93 2.06 13.00
Intensity of Patients n. Median TS/RT Min Max
staining Ratio
Gr.1: 0 – 1+ 12 0.80 0.11 6.24
Gr.2: 2+ 16 3.93 0.41 11.74
Gr.3: 3+ – 4+ 15 4.93 2.06 13.00
Table II. Polymorphism in the 3’UTR of the TS gene in MSS and MSI
colorectal cancer.
TS genotype
+6bp/+6bp +6bp/- 6bp - 6bp/- 6bp
MSI 19 (56.5%) 11 (34.8%) 3 (8.7%)
MSS 14 (52.6%) 9 (31.6%) 4 (15.8%)
Total 33 20 7
Figure 2. Colorectal cancers showed different TS mRNA levels according
to their 5’UTR polymorphism (p<0.004). Levels were significantly higher
in tumours harbouring triple repeats (3R) compared with those
homozygous for 2R.
Immunohistochemical determination of TS. Three micron sections
from formalin-fixed tissue blocks, dewaxed and rehydrated, were
used. Antigen retrieval was carried out using Dako antigen
retrieval fluid and microwaving at full power for a total of 15
minutes, in three 5-minute sessions, adding distilled water during
the break between each microwaving. Sections were then treated
with 3% hydrogen peroxidase for 5 minutes, followed by TS 106
(purchased from NeoMarkers) antibody to TS at a dilution 1:10
overnight at 4ÆC. Visualization was obtained by incubation with
anti-mouse rabbit and goat antibody (Dako) for 15 minutes,
followed by a streptavidin-biotin peroxidase complex (Dako) for 15
minutes and, finally, Dako chromogen for 5 minutes. Mayer’s
haematoxylin was used to counterstain the sections. As a positive
control, lymphoid germinal centre cells and normal mucous glands
were used for TS.
The TS staining positivity was semi-quantitatively evaluated as
follows:
Intensity of staining. A semi-quantitative score was adapted from
1+ to 4+ for positive cases: lack of staining was classified as 0.
Percentage of staining. A semi-quantitative score was adopted: 1
(less than 10% tumour cells stained) to 4+ (all cells stained). Lack
of staining was classified as 0. The immunohistochemical assay was
performed in 43 patients.
Statistical analysis. The relationship between the TS genotype
regarding the 5'UTR polymorphism or the 3'UTR polymorphism
and the MSI status was analysed using a contingency table analysis
with Chi-squared test. To show any relationship between the
quantification of the TS mRNA levels by LightCycler assay with
the immunohistochemical one, the Mann-Whitney test was
adopted. To investigate the relationships between TS genotype or
MSI status and the TS expression as measured by LightCycler
PCR, a Kruskal-Wallis test was performed followed by a Wilcoxon-
Mann-Whitney test as appropriate. Calculations were performed
using a commercially available computer program (JMP 5.0, SAS
Institute Inc, Cary, NC, USA). p values < 0.05 were considered to
be statistically significant.
Results
Polymorphism in the number of the TS repeat sequences in its
5' UTR and MSI status in human colorectal cancer. The TS
genotype in 80 samples of DNA isolated from CRC cancer
tissues using the PCR assay was analysed. Of those 80
cancer samples, 48 were MSI and 32 MSS. In the 5' UTR of
the TS gene (Figure 1A) we found a PCR product of 144bp
in those cancer samples homozygous for the triple repeat
(3R/3R), a PCR product of 116bp in those homozygous for
the double repeat (2R/2R), while both PCR products (144
and 116bp) were present in heterozygous cancer samples
(2R/3R). In Table I is shown the rate of each genotype and
its distribution into MSI and MSS cases. We did not find
any relationship between the MSI status and the number of
repeats in the 5'UTR (p=0.22).
Polymorphism in the number of TS repeat sequences in its 3'
UTR and MSI status in human colorectal cancer. We
evaluated the presence of the 6bp fragment in the 3'UTR
region of the TS gene (Figure 1B) in 60 tumour cancer
samples from patients bearing CRC (33 MSI and 27 MSS).
The tumour samples homozygous for the 6bp insertion
(+6bp/+6bp) displayed two fragments of 70 and 88 bp,
tumour samples homozygous for the 6 bp deletion,
displayed a 152 bp PCR product, while cancer
heterozygous samples displayed a combination of the three
fragments (70, 88 and 152 bp). In Table II is shown the
rate of each genotype and its distribution to MSI and MSS
cases. In the 3'UTR region we also did not find any
association between the presence or absence of 6bp-insert
and the MSI status (p=0.55).
Evaluation of the TS mRNA levels. We performed the 
TS mRNA levels from 80 CRC samples by means of real-
time PCR on a LightCycler. We found different significant
TS mRNA expression (p<0.004) in tumours with
increasing copy-number of repeats (2R/2R versus 2R/3R
versus 3R/3R). Moreover, we found significantly higher 
TS mRNA levels in the 2R/3R group (p<0.026) and in the
3R/3R group (p<0.001) compared with the 2R/2R group
(Figure 2).
We did not find any relationship between the
polymorphism of the 3' UTR and the TS mRNA levels
(p=0.65) or between the TS mRNA expression with the
MSS and MSI status (p=0.56).
Immunohistochemical determination of TS expression. We
determined immunohistochemically the TS expression in 43
CRC samples (from the same patients in which the TS
mRNA levels were evaluated by means of LightCycler
(Table III).
Discussion
Genetic polymorphisms in the gene encoding TS have been
shown to influence the response to 5-FU therapy. Multiple
studies have demonstrated that both the TS mRNA and
protein levels are inversely related to clinical antitumour
response; indeed, survival of patients with advanced
colorectal cancer is inferior if high TS expression is present
(24, 25). The expression of TS is controlled, in part, by a
polymorphism characterized by a multiple number of
tandem repeats of a 28-bp sequence in the 5'-promoter
enhancer region (TSER) of the gene.
There have been many studies which all suggest that
patients homozygous for TSER*3 have a higher TS activity
and a poorer response to 5-FU therapy than patients
homozygous for TSER*2. In one study involving 65 rectal
cancer patients, the probability of achieving tumour
downstaging after radiation and 5-FU treatment was
dependent on TSER genotype. TSER*2 carriers exhibited
a 3.7-fold higher probability of achieving downstaging (a
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measure of therapeutic success) when compared to
TSER*3 homozygotes (26). Marsh et al. (20) also showed
that TSER genotypes correlated with tumour response
after 5-FU treatment in 24 metastasis colorectal cancer
patients. This study showed that the TSER*2/TSER*2
genotype was nearly twice as common in the responders to
chemotherapy compared to non-responders (40% vs. 22%,
respectively), and also showed a decrease in median
survival with increasing numbers of TSER repeats (median
survival 16 months for TSER*2/TSER*2, 14 months for
TSER*2/TSER*3, 12 months for TSER*3/TSER*3). This
is confirmed by Pullarkat et al. (17) who showed that, in 50
patients receiving 5-FU for metastatic colorectal cancer,
there was a higher response rate in patients with lower
numbers of TSER repeats (50% for TSER*2/TSER*2,
15% for TSER*2/TSER*3 and 9% for TSER*3/TSER*3).
These studies suggest that combined genotyping of TSER
functional variants might be useful in selecting patients
who are likely to tolerate and respond to 5-FU therapy.
This is particularly important because of the availability of
other active antitumour agents (i.e., irinotecan,
oxaliplatin), which can be used in combination with or in
place of 5-FU if high TS is detected. In the present study,
we therefore tested the hypothesis that there is an
association between TS expression and MSI phenotype in
colorectal carcinoma.
As described above, the TS expression depends on the
genotype of the 5’UTR enhancer region of the
corresponding gene. Recently, another polymorphism in the
3’UTR of the TS gene was described (18). Although the
3’end of the mRNA is non-coding, it may contain sequences
determining mRNA stability or translational efficiency.
Therefore, we investigated the frequency of both
polymorphisms in 80 (60) samples of CRC of which 48 (33)
showed microsatellite instability. The results show no
significant correlation between the 5’UTR polymorphism
and the MSI phenotype, nor between the 3’UTR
polymorphism and the MSI phenotype. 
To include unknown putative associations between MSI
and TS, we investigated the correlation between TS mRNA
level and MSI status by means of real-time quantitative
PCR with the LightCycler System (Roche). Again, no
significant correlation was seen.
Interestingly, we observed an overall higher mRNA level
together with an increasing number of repeats in the
5’UTR. This finding was indepent of MSI status. Pullarkat
et al. (17) also found the 28 bp tandem repeat to be
associated with intratumoural TS mRNA levels. The
mechanism of this regulatory effect is not yet clear. It has
been suggested, by Marsh et al. (20), that the tandem
repeats could form stem loop structures with an inverted
repeat sequence located upstream from the enhancer
region, thus allowing more efficient translation of TS
mRNA. Our results suggest that an increased number of
repeats in the enhancer region of the TS gene leads to
enhanced cellular mRNA levels.
The major finding of our work was a lack of correlation
between MSI and TS expression or TS polymorphisms. Our
results suggest that the higher efficiency of 5-FU therapy in
microsatellite unstable CRC is not associated with TS
expression, but is due to other mechanisms which need
further study for clarification, and that the evaluation of the
TS expression by means of immunohistochemistry assay
remains a safe and reliable method in CRC. 
In accordance with others, we conclude that evaluating
the TS genotype with regard to the 5’UTR or measuring
intratumoural mRNA levels may become a useful tool to
predict the response to 5-FU and to stratify patients for
appropriate chemotherapy.
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